Stockreport

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF - Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies - POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (NYSE America [Read more]